Loading...
•
Mar 31, 2024
Exact Sciences Q1 2024 Earnings Report
Exact Sciences reported a revenue increase driven by growth in screening and precision oncology segments.
Key Takeaways
Exact Sciences announced first-quarter 2024 results with a total revenue of $638 million, a 6% increase compared to the same period in 2023. The company maintains its full-year 2024 revenue and adjusted EBITDA guidance.
Total first-quarter revenue reached $638 million, reflecting a 6% increase year-over-year.
Screening revenue amounted to $475 million, a 7% increase compared to the previous year.
Precision Oncology revenue was $163 million, marking a 5% increase.
The company maintains full-year 2024 revenue and adjusted EBITDA guidance.
Exact Sciences
Exact Sciences
Exact Sciences Revenue by Segment
Revenue by Segment
Screening Revenue
CapyFin.comPrecision Oncology Revenue
CapyFin.com Forward Guidance
The company has maintained its revenue guidance of $2.810-$2.850 billion during 2024.
Positive Outlook
- Screening revenue of $2.155-$2.175 billion.
- Precision Oncology revenue of $655-$675 million.
- Maintained full-year revenue guidance.
- Maintained adjusted EBITDA guidance.
- Continued investment in innovative solutions.
Challenges Ahead
- Potential impacts from macroeconomic conditions.
- Risks associated with development and commercialization of new products.
- Competition for products and services.
- Reliance on certain suppliers.
- Potential effects of judicial, executive, or legislative actions.
Revenue & Expenses
Visualization of income flow from segment revenue to net income